- Home
- TOPS vs RLYB Comparison
TOPS vs RLYB Comparison
Compare TOPS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- RLYB
- Stock Information
- Founded
- TOPS 2000
- RLYB 2018
- Country
- TOPS Greece
- RLYB United States
- Employees
- TOPS N/A
- RLYB 25
- Industry
- TOPS Marine Transportation
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- RLYB Health Care
- Exchange
- TOPS Nasdaq
- RLYB Nasdaq
- Market Cap
- TOPS 28.3M
- RLYB 25.0M
- IPO Year
- TOPS 2004
- RLYB 2021
- Fundamental
- Price
- TOPS $5.96
- RLYB $0.46
- Analyst Decision
- TOPS
- RLYB Buy
- Analyst Count
- TOPS 0
- RLYB 5
- Target Price
- TOPS N/A
- RLYB $9.75
- AVG Volume (30 Days)
- TOPS 9.0K
- RLYB 47.4K
- Earning Date
- TOPS 04-15-2025
- RLYB 05-08-2025
- Dividend Yield
- TOPS N/A
- RLYB N/A
- EPS Growth
- TOPS N/A
- RLYB N/A
- EPS
- TOPS N/A
- RLYB N/A
- Revenue
- TOPS $83,870,000.00
- RLYB $636,000.00
- Revenue This Year
- TOPS $7.10
- RLYB N/A
- Revenue Next Year
- TOPS $6.54
- RLYB N/A
- P/E Ratio
- TOPS N/A
- RLYB N/A
- Revenue Growth
- TOPS 1.10
- RLYB N/A
- 52 Week Low
- TOPS $5.30
- RLYB $0.54
- 52 Week High
- TOPS $14.24
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- TOPS 40.39
- RLYB 45.84
- Support Level
- TOPS $6.33
- RLYB $0.54
- Resistance Level
- TOPS $6.55
- RLYB $0.71
- Average True Range (ATR)
- TOPS 0.20
- RLYB 0.08
- MACD
- TOPS -0.01
- RLYB -0.00
- Stochastic Oscillator
- TOPS 12.73
- RLYB 39.07
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.